Document Detail

Dosimetry of (223)Ra-chloride: dose to normal organs and tissues.
MedLine Citation:
PMID:  23053328     Owner:  NLM     Status:  Publisher    
PURPOSE: (223)Ra-Chloride (also called Alpharadin®) targets bone metastases with short range alpha particles. In recent years several clinical trials have been carried out showing, in particular, the safety and efficacy of palliation of painful bone metastases in patients with castration-resistant prostate cancer using (223)Ra-chloride. The purpose of this work was to provide a comprehensive dosimetric calculation of organ doses after intravenous administration of (223)Ra-chloride according to the present International Commission on Radiological Protection (ICRP) model for radium. METHODS: Absorbed doses were calculated for 25 organs or tissues. RESULTS: Bone endosteum and red bone marrow show the highest dose coefficients followed by liver, colon and intestines. After a treatment schedule of six intravenous injections with 0.05 MBq/kg of (223)Ra-chloride each, corresponding to 21 MBq for a 70 kg patient, the absorbed alpha dose to the bone endosteal cells is about 16 Gy and the corresponding absorbed dose to the red bone marrow is approximately 1.5 Gy. CONCLUSION: The comprehensive list of dose coefficients presented in this work will assist in comparing and evaluating organ doses from various therapy modalities used in nuclear medicine and will provide a base for further development of patient-specific dosimetry.
Michael Lassmann; Dietmar Nosske
Related Documents :
8255478 - Catechol-o-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in ...
2054538 - Treatment of opiate withdrawal on entry to prison.
1639618 - Visual acuities and scotomas after one week levodopa administration in human amblyopia.
7055528 - Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: clin...
24933228 - Toxicological evaluation of the hydroethanolic extract of dilodendron bipinnatum radlk.
1354618 - Acute effect of an alpha 1-adrenoceptor antagonist on urinary sodium excretion, plasma ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-11
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  -     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Nuclear Medicine, University of Würzburg, 97080, Würzburg, Germany,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  [(18)F]FLT is superior to [(18)F]FDG for predicting early response to antiproliferative treatment in...
Next Document:  New pathogenetic insights into pseudoexfoliation syndrome/glaucoma : Therapeutically relevant?